Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia
NCT ID: NCT00981123
Last Updated: 2011-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2009-09-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended
NCT00922090
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
NCT04115319
A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia
NCT01214135
Seroquel Long-Term NIS for Schizophrenia Patients
NCT00523783
Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia
NCT01213836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are already treated with quetiapine for at least 12 weeks (outpatients or hospitalised patients)
* Patients capable of signing ICF
Exclusion Criteria
* Patients with contraindication for quetiapine therapy according to the approved SmPC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ana Marija Gjurovic, MD, MSc
Role: STUDY_DIRECTOR
AstraZeneca Medical Department
Andreja Hasenohrl, DVM
Role: STUDY_CHAIR
AstraZeneca Medical Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Bjelovar, , Croatia
Research Site
Čakovec, , Croatia
Research Site
Dubrovnik, , Croatia
Research Site
Karlovac, , Croatia
Research Site
Osijek, , Croatia
Research Site
Popovača, , Croatia
Research Site
Pula, , Croatia
Research Site
Rijeka, , Croatia
Research Site
Sisak, , Croatia
Research Site
Slavonski Brod, , Croatia
Research Site
Split, , Croatia
Research Site
Šibenik, , Croatia
Research Site
Varaždin, , Croatia
Research Site
Vinkovci, , Croatia
Research Site
Vukovar, , Croatia
Research Site
Zabok, , Croatia
Research Site
Zadar, , Croatia
Research Site
Zagreb, , Croatia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NHR-SER-2009/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.